131 related articles for article (PubMed ID: 24612434)
21. The cytogenetic relationship between primary and recurrent meningiomas points to the need for new treatment strategies in cases at high risk of relapse.
Espinosa AB; Tabernero MD; Maíllo A; Sayagués JM; Ciudad J; Merino M; Alguero MC; Lubombo AM; Sousa P; Santos-Briz A; Orfao A
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):772-80. PubMed ID: 16467088
[TBL] [Abstract][Full Text] [Related]
22. Gene expression profiles of metabolic aggressiveness and tumor recurrence in benign meningioma.
Serna E; Morales JM; Mata M; Gonzalez-Darder J; San Miguel T; Gil-Benso R; Lopez-Gines C; Cerda-Nicolas M; Monleon D
PLoS One; 2013; 8(6):e67291. PubMed ID: 23840654
[TBL] [Abstract][Full Text] [Related]
23. Chromosomal and genetic aberrations differ with meningioma subtype.
Wada K; Maruno M; Suzuki T; Kagawa N; Hashiba T; Fujimoto Y; Hashimoto N; Izumoto S; Yoshimine T
Brain Tumor Pathol; 2004; 21(3):127-33. PubMed ID: 15696974
[TBL] [Abstract][Full Text] [Related]
24. Recurrence of benign meningiomas: predictive value of proliferative index, BCL2, p53, hormonal receptors and HER2 expression.
Abdelzaher E; El-Gendi SM; Yehya A; Gowil AG
Br J Neurosurg; 2011 Dec; 25(6):707-13. PubMed ID: 20979437
[TBL] [Abstract][Full Text] [Related]
25. Platelet-derived growth factor (PDGF) and receptor (PDGFR) expression in human meningiomas: correlations with clinicopathological features and cytogenetic analysis.
Figarella-Branger D; Vagner-Capodano AM; Bouillot P; Graziani N; Gambarelli D; Devictor B; Zattara-Cannoni H; Bianco N; Grisoli F; Pellissier JF
Neuropathol Appl Neurobiol; 1994 Oct; 20(5):439-47. PubMed ID: 7531297
[TBL] [Abstract][Full Text] [Related]
26. Deletion of chromosome 1p and loss of expression of alkaline phosphatase indicate progression of meningiomas.
Müller P; Henn W; Niedermayer I; Ketter R; Feiden W; Steudel WI; Zang KD; Steilen-Gimbel H
Clin Cancer Res; 1999 Nov; 5(11):3569-77. PubMed ID: 10589773
[TBL] [Abstract][Full Text] [Related]
27. Her-2/neu gene amplification in paraffin-embedded tissue sections of meningioma patients.
Ozer O; Sahin FI; Aydemir F; Ozen O; Yilmaz Z; Altinörs N
Turk Neurosurg; 2009 Apr; 19(2):135-8. PubMed ID: 19431122
[TBL] [Abstract][Full Text] [Related]
28. Genetic changes with prognostic value in histologically benign meningiomas.
Barbera S; San Miguel T; Gil-Benso R; Muñoz-Hidalgo L; Roldan P; Gonzalez-Darder J; Cerda-Nicolas M; Lopez-Gines C
Clin Neuropathol; 2013; 32(4):311-7. PubMed ID: 23442303
[TBL] [Abstract][Full Text] [Related]
29. Characterization of chromosome 14 abnormalities by interphase in situ hybridization and comparative genomic hybridization in 124 meningiomas: correlation with clinical, histopathologic, and prognostic features.
Tabernero MD; Espinosa AB; Maíllo A; Sayagués JM; Alguero Mdel C; Lumbreras E; Díaz P; Gonçalves JM; Onzain I; Merino M; Morales F; Orfao A
Am J Clin Pathol; 2005 May; 123(5):744-51. PubMed ID: 15981814
[TBL] [Abstract][Full Text] [Related]
30. Histologically benign metastatic meningioma: morphological and cytogenetic study. Case report.
Cerdá-Nicolás M; Lopez-Gines C; Perez-Bacete M; Roldan P; Talamantes F; Barberá J
J Neurosurg; 2003 Jan; 98(1):194-8. PubMed ID: 12546373
[TBL] [Abstract][Full Text] [Related]
31. Expression of ErbB-1 and ErbB-2 in meningioma.
Wickremesekera A; Hovens CM; Kaye AH
J Clin Neurosci; 2010 Sep; 17(9):1155-8. PubMed ID: 20547458
[TBL] [Abstract][Full Text] [Related]
32. [Cytogenetic alterations in meningioma tumors and their impact on disease outcome].
Sayagués JM; Tabernero MD; Maíllo A
Med Clin (Barc); 2007 Feb; 128(6):226-32. PubMed ID: 17335728
[TBL] [Abstract][Full Text] [Related]
33. A study of meningiomas in South Africa: investigating a correlation between clinical presentation, histopathology and genetic markers.
Vivier J; Bardien S; Van der Merwe L; Brusnicky J; Zaharie D; Keyser R; Hewlett R; de Jong G; Hartzenberg B
Br J Neurosurg; 2009 Feb; 23(1):63-70. PubMed ID: 19234911
[TBL] [Abstract][Full Text] [Related]
34. Multiplatform profiling of meningioma provides molecular insight and prioritization of drug targets for rational clinical trial design.
Everson RG; Hashimoto Y; Freeman JL; Hodges TR; Huse J; Zhou S; Xiu J; Spetzler D; Sanai N; Kim L; Kesari S; Brenner A; De Monte F; Heimberger A; Raza SM
J Neurooncol; 2018 Sep; 139(2):469-478. PubMed ID: 29846894
[TBL] [Abstract][Full Text] [Related]
35. Clonal cytogenetic progression within intratumorally heterogeneous meningiomas predicts tumor recurrence.
Urbschat S; Rahnenführer J; Henn W; Feiden W; Wemmert S; Linsler S; Zang KD; Oertel J; Ketter R
Int J Oncol; 2011 Dec; 39(6):1601-8. PubMed ID: 21922133
[TBL] [Abstract][Full Text] [Related]
36. An immunohistochemical study of HER2 expression in meningioma and its correlation with tumor grade.
Mahzouni P; Movahedipour M
Pathol Res Pract; 2012 Apr; 208(4):221-4. PubMed ID: 22420924
[TBL] [Abstract][Full Text] [Related]
37. Meningiomas: karyotypes and histological patterns.
Lopez-Gines C; Piquer J; Cerda-Nicolas M; Barcia-Salorio J; Barcia-Marino C
Clin Neuropathol; 1989; 8(3):130-3. PubMed ID: 2743649
[TBL] [Abstract][Full Text] [Related]
38. Differential expression of extracellular matrix-related genes in rare variants of meningioma.
Kwon MJ; Sung CO; Kang SY; Do IG; Suh YL
Hum Pathol; 2013 Feb; 44(2):260-8. PubMed ID: 22995327
[TBL] [Abstract][Full Text] [Related]
39. Loss of material from chromosome arm 1p during malignant progression of meningioma revealed by fluorescent in situ hybridization.
Ishino S; Hashimoto N; Fushiki S; Date K; Mori T; Fujimoto M; Nakagawa Y; Ueda S; Abe T; Inazawa J
Cancer; 1998 Jul; 83(2):360-6. PubMed ID: 9669820
[TBL] [Abstract][Full Text] [Related]
40. Cytogenetic and proliferative potentials in meningiomas.
Debiec-Rychter M; Biernat W; Limon J; Kordek R; Izycka E; Borowska-Lehman J; Imieliński B; Liberski PP
Pol J Pathol; 1999; 50(4):243-8. PubMed ID: 10721264
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
